1
|
Garcia Ricardez GA, Koganti N, Yang PC, Okada S, Uriguen Eljuri PM, Yasuda A, El Hafi L, Yamamoto M, Takamatsu J, Ogasawara T. Adaptive motion generation using imitation learning and highly compliant end effector for autonomous cleaning. Adv Robot 2019. [DOI: 10.1080/01691864.2019.1698461] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- G. A. Garcia Ricardez
- Division of Information Science, Nara Institute of Science and Technology, Ikoma, Japan
| | - N. Koganti
- Division of Information Science, Nara Institute of Science and Technology, Ikoma, Japan
| | - P.-C. Yang
- Business Innovation Division, Panasonic Corporation, Osaka, Japan
| | - S. Okada
- Business Innovation Division, Panasonic Corporation, Osaka, Japan
| | - P. M. Uriguen Eljuri
- Division of Information Science, Nara Institute of Science and Technology, Ikoma, Japan
| | - A. Yasuda
- Division of Information Science, Nara Institute of Science and Technology, Ikoma, Japan
| | - L. El Hafi
- College of Information Science and Engineering, Ritsumeikan University, Kusatsu, Japan
| | - M. Yamamoto
- Business Innovation Division, Panasonic Corporation, Osaka, Japan
| | - J. Takamatsu
- Division of Information Science, Nara Institute of Science and Technology, Ikoma, Japan
| | - T. Ogasawara
- Division of Information Science, Nara Institute of Science and Technology, Ikoma, Japan
| |
Collapse
|
2
|
Garcia Ricardez GA, Okada S, Koganti N, Yasuda A, Uriguen Eljuri PM, Sano T, Yang PC, El Hafi L, Yamamoto M, Takamatsu J, Ogasawara T. Restock and straightening system for retail automation using compliant and mobile manipulation. Adv Robot 2019. [DOI: 10.1080/01691864.2019.1698460] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- G. A. Garcia Ricardez
- Division of Information Science, Nara Institute of Science and Technology, Ikoma, Japan
| | - S. Okada
- Business Innovation Division, Panasonic Corporation, Osaka, Japan
| | - N. Koganti
- Division of Information Science, Nara Institute of Science and Technology, Ikoma, Japan
| | - A. Yasuda
- Division of Information Science, Nara Institute of Science and Technology, Ikoma, Japan
| | - P. M. Uriguen Eljuri
- Division of Information Science, Nara Institute of Science and Technology, Ikoma, Japan
| | - T. Sano
- Division of Information Science, Nara Institute of Science and Technology, Ikoma, Japan
| | - P.-C. Yang
- Business Innovation Division, Panasonic Corporation, Osaka, Japan
| | - L. El Hafi
- College of Information Science and Engineering, Ritsumeikan University, Kusatsu, Japan
| | - M. Yamamoto
- Business Innovation Division, Panasonic Corporation, Osaka, Japan
| | - J. Takamatsu
- Division of Information Science, Nara Institute of Science and Technology, Ikoma, Japan
| | - T. Ogasawara
- Division of Information Science, Nara Institute of Science and Technology, Ikoma, Japan
| |
Collapse
|
3
|
Shinkoda Y, Shirahata A, Fukutake K, Takamatsu J, Shima M, Hanabusa H, Mugishima H, Takedani H, Kawasugi K, Taki M, Matsushita T, Tawa A, Nogami K, Higasa S, Kosaka Y, Fujii T, Sakai M, Migita M, Uchiba M, Kawakami K, Sameshima K, Ohashi Y, Saito H. A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors. Haemophilia 2016; 23:59-66. [DOI: 10.1111/hae.13050] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/16/2016] [Indexed: 11/27/2022]
Affiliation(s)
- Y. Shinkoda
- Department of Paediatrics; Kagoshima City Hospital; Kagoshima Japan
| | - A. Shirahata
- Kitakyushu Yahata Higashi Hospital; Kitakyushu Fukuoka Japan
| | - K. Fukutake
- Department of Laboratory Medicine; Tokyo Medical University; Tokyo Japan
| | - J. Takamatsu
- Japanese Red Cross Tokai-Hokuriku Block Blood Center; Seto Aichi Japan
| | - M. Shima
- Department of Paediatrics; Nara Medical University; Kashihara Nara Japan
| | - H. Hanabusa
- Department of Haematology; Ogikubo Hospital; Tokyo Japan
| | - H. Mugishima
- Department of Paediatrics; Nihon University Itabashi Hospital; Tokyo Japan
| | - H. Takedani
- Department of Joint Surgery; Research Hospital of the Institute of Medical Science; the University of Tokyo; Tokyo Japan
| | - K. Kawasugi
- Department of Internal Medicine; Teikyo University Hospital; Tokyo Japan
| | - M. Taki
- Department of Paediatrics; St. Marianna University School of Medicine; Kawasaki Kanagawa Japan
| | - T. Matsushita
- Department of Transfusion Medicine; Nagoya University Hospital; Nagoya Aichi Japan
| | - A. Tawa
- Department of Paediatrics; National Hospital Organization Osaka National Hospital; Osaka Japan
| | - K. Nogami
- Department of Paediatrics; Nara Medical University; Kashihara Nara Japan
| | - S. Higasa
- Division of Haematology; Department of Internal Medicine; Hyogo College of Medicine; Nishinomiya Hyogo Japan
| | - Y. Kosaka
- Department of Haematology and Oncology; Kobe Children's Hospital; Kobe Hyogo Japan
| | - T. Fujii
- Division of Blood Transfusion; Hiroshima University Hospital; Hiroshima Japan
| | - M. Sakai
- Department of Paediatrics; University of Occupational and Environmental Health; Kitakyushu Fukuoka Japan
| | - M. Migita
- Department of Paediatrics; Kumamoto Red Cross Hospital; Kumamoto Japan
| | - M. Uchiba
- Department of Blood Transfusion and Cell Therapy; Kumamoto University Hospital; Kumamoto Japan
| | - K. Kawakami
- Department of Paediatrics; Kagoshima City Hospital; Kagoshima Japan
| | - K. Sameshima
- Department of Paediatrics; Kagoshima City Hospital; Kagoshima Japan
| | - Y. Ohashi
- Department of Biostatistics; School of Public Health; the University of Tokyo; Tokyo Japan
| | - H. Saito
- National Hospital Organization Nagoya Medical Center; Nagoya Aichi Japan
| |
Collapse
|
4
|
Shirahata A, Fukutake K, Takamatsu J, Shima M, Hanabusa H, Mugishima H, Amano K, Takedani H, Tamashima S, Matsushita T, Tawa A, Tanaka I, Higasa S, Kosaka Y, Fujii T, Sakai M, Migita M, Kawakami K, Ohashi Y, Saito H. A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics. Haemophilia 2013; 19:853-60. [DOI: 10.1111/hae.12205] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/13/2013] [Indexed: 11/29/2022]
Affiliation(s)
- A. Shirahata
- Kitakyushu Yahata Higashi Hospital; Kitakyushu Fukuoka
| | - K. Fukutake
- Department of Laboratory Medicine; Tokyo Medical University; Tokyo
| | - J. Takamatsu
- Japanese Red Cross Aichi Blood Center; Seto Aichi
| | - M. Shima
- Department of Paediatrics; Nara Medical University; Kashihara Nara
| | - H. Hanabusa
- Department of Haematology; Ogikubo Hospital; Tokyo
| | - H. Mugishima
- Department of Paediatrics; Nihon University Itabashi Hospital; Tokyo
| | - K. Amano
- Department of Laboratory Medicine; Tokyo Medical University; Tokyo
| | - H. Takedani
- Department of Joint Surgery; Research Hospital of the Institute of Medical Science; The University of Tokyo; Tokyo
| | - S. Tamashima
- Department of Haematology and Oncology; Seirei Hamamatsu General Hospital; Hamamatsu Shizuoka
| | - T. Matsushita
- Department of Transfusion Medicine; Nagoya University Hospital; Nagoya
| | - A. Tawa
- Department of Paediatrics; National Hospital Organization Osaka National Hospital; Osaka
| | - I. Tanaka
- Department of Paediatrics; Nara Medical University; Kashihara Nara
| | - S. Higasa
- Division of Haematology; Department of Internal Medicine; Hyogo College of Medicine; Nishinomiya Hyogo
| | - Y. Kosaka
- Department of Haematology and Oncology; Kobe Children's Hospital; Kobe
| | - T. Fujii
- Division of the Blood Transfusion; Hiroshima University Hospital; Hiroshima
| | - M. Sakai
- Department of Paediatrics; University of Occupational and Environmental Health; Kitakyushu Fukuoka
| | - M. Migita
- Department of Paediatrics; Kumamoto Red Cross Hospital; Kumamoto
| | - K. Kawakami
- Department of Paediatrics; Kagoshima City Hospital; Kagoshima
| | - Y. Ohashi
- Department of Biostatistics; School of Public Health; The University of Tokyo; Tokyo
| | - H. Saito
- National Hospital Organization Nagoya Medical Center; Nagoya Japan
| |
Collapse
|
5
|
Shirahata A, Fukutake K, Mimaya J, Takamatsu J, Shima M, Hanabusa H, Takedani H, Takashima Y, Matsushita T, Tawa A, Higasa S, Takata N, Sakai M, Kawakami K, Ohashi Y, Saito H. Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors-phase I trial: 2nd report. Haemophilia 2012; 19:330-7. [DOI: 10.1111/hae.12024] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/15/2012] [Indexed: 11/27/2022]
Affiliation(s)
- A. Shirahata
- Department of Paediatrics; University of Occupational and Environmental Health; Kitakyushu; Fukuoka; Japan
| | - K. Fukutake
- Department of Laboratory Medicine; Tokyo Medical University; Tokyo; Japan
| | - J. Mimaya
- Division of Haematology and Oncology; Shizuoka Children's Hospital; Shizuoka; Japan
| | - J. Takamatsu
- Department of Transfusion Medicine; Nagoya University Hospital; Nagoya; Japan
| | - M. Shima
- Department of Paediatrics; Nara Medical University; Kashihara; Nara; Japan
| | - H. Hanabusa
- Department of Haematology; Ogikubo Hospital; Tokyo; Japan
| | - H. Takedani
- Department of Joint Surgery, Research Hospital of the Institute of Medical Science; the University of Tokyo; Tokyo; Japan
| | - Y. Takashima
- Division of Haematology and Oncology; Shizuoka Children's Hospital; Shizuoka; Japan
| | - T. Matsushita
- Department of Haematology and Oncology; Nagoya University Graduate School of Medicine; Nagoya; Japan
| | - A. Tawa
- Department of Paediatrics; National Hospital Organization Osaka National Hospital; Osaka; Japan
| | - S. Higasa
- Division of Haematology, Department of Internal Medicine; Hyogo College of Medicine; Nishinomiya; Hyogo; Japan
| | - N. Takata
- Division of the Blood Transfusion Services; Hiroshima University Hospital; Hiroshima; Japan
| | - M. Sakai
- Department of Paediatrics; University of Occupational and Environmental Health; Kitakyushu; Fukuoka; Japan
| | - K. Kawakami
- Department of Paediatrics; Kagoshima City Hospital; Kagoshima; Japan
| | - Y. Ohashi
- Department of Biostatistics, School of Public Health; the University of Tokyo; Tokyo; Japan
| | - H. Saito
- Nagoya Central Hospital; Nagoya; Japan
| |
Collapse
|
6
|
Iwaki T, Tanaka A, Miyawaki Y, Suzuki A, Kobayashi T, Takamatsu J, Matsushita T, Umemura K, Urano T, Kojima T, Terao T, Kanayama N. Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans. J Thromb Haemost 2011; 9:1200-6. [PMID: 21486382 DOI: 10.1111/j.1538-7836.2011.04288.x] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Plasminogen activator inhibitor-1 (PAI-1) is the primary physiological regulator of urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA) activity. A number of studies have shown that elevated levels of PAI-1 are related to pathological states such as an increased risk of arterial thrombotic events and a poor prognosis for cancer patients; however, there are few reports about PAI-1 deficiency in humans because the disorder is very rare. OBJECTIVE To understand the in vivo impact of a complete PAI-1 deficiency, Serpine1(-/-) mice were generated; a number of in vivo studies have been conducted to elucidate the function of PAI-1 using Serpine1(-/-) mice. The phenotypes demonstrated in Serpine1(-/-) mice, however, were quite different from those in humans. Therefore, it is necessary to find out and analyze SERPINE1 deficiency in humans. PATIENT AND METHODS The patient is a 47-year-old woman who has had multiple episodes of major bleeding. Although most of the patient's blood coagulation factors were functionally normal, her PAI-1 antigen levels were undetectable. Therefore, DNA sequencing of the SERPINE1 gene were analyzed. RESULTS The proband had a homozygous 1-bp duplication (C) at exon 3 (c.356dupC; p.Ile120AspfsX42). Both wild-type PAI-1 (42.7 kDa) and mutated (Mut) PAI-1 (14.7kDa) were expressed in COS-1 cells, although the level of Mut PAI-1 expressed in the cell lysates was much lower. Wild-type PAI-1 was observed in the culture supernatant, whereas no Mut PAI-1 was detected in the supernatant. CONCLUSIONS Considering the results of the present study, the translation of mouse studies to humans must be performed with great care.
Collapse
Affiliation(s)
- T Iwaki
- Department of Pharmacology, Hamamatsu University School of Medicine, Hamamatsu Shizuoka, Japan.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Terao T, Oike J, Kobayashi T, Imai N, Manabe O, Koie K, Kamiya T, Takamatsu J. Pregnancy complicated by idiopathic thrombocytopenic purpura. J OBSTET GYNAECOL 2009. [DOI: 10.3109/01443618109067397] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
8
|
Fujii Y, Shibata Y, Miyata S, Inaba S, Asai T, Hoshi Y, Takamatsu J, Takahashi K, Ohto H, Juji T, Sagawa K. Consecutive national surveys of ABO-incompatible blood transfusion in Japan. Vox Sang 2009; 97:240-6. [PMID: 19476605 DOI: 10.1111/j.1423-0410.2009.01199.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND AND OBJECTIVES Morbidity and mortality from ABO-incompatible transfusion persist as consequences of human error. Even so, insufficient attention has been given to improving transfusion safety within the hospital. MATERIALS AND METHODS National surveys of ABO-incompatible blood transfusions were conducted by the Japanese Society of Blood Transfusion, with support from the Ministry of Health, Labor and Welfare. Surveys concluded in 2000 and 2005 analysed ABO-incompatible transfusion data from the previous 5 years (January 1995 to December 1999 and January 2000 to December 2004, respectively). The first survey targeted 777 hospitals and the second, 1355 hospitals. Data were collected through anonymous questionnaires. RESULTS The first survey achieved a 77.4% response rate (578 of 777 hospitals). The second survey collected data from 251 more hospitals, but with a lower response rate (61.2%, or 829 of 1355 hospitals). The first survey analysed 166 incidents from 578 hospitals, vs. 60 incidents from 829 hospitals in the second survey. The main cause of ABO-incompatible transfusion was identification error between patient and blood product: 55% (91 of 166) in the first survey and 45% (27 of 60) in the second. Patient outcomes included nine preventable deaths from 1995 to 1999, and eight preventable deaths from 2000 to 2004. CONCLUSION Misidentification at the bedside persists as the main cause of ABO-incompatible transfusion.
Collapse
Affiliation(s)
- Y Fujii
- Department of Blood Transfusion, Yamaguchi University Hospital, Yamaguchi, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Ino Y, Oka T, Nomura K, Watanabe T, Kawashima S, Amano T, Hayashi Y, Okabe A, Uehara Y, Masuda T, Takamatsu J, Nakazawa A, Ikeuchi K, Endo H, Fukuta K, Akishinonomiya F. Breed differentiation among Japanese native chickens by specific skull features determined by direct measurements and computer vision techniques. Br Poult Sci 2008; 49:273-81. [PMID: 18568751 DOI: 10.1080/00071660802094727] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
1. Inter-breed morphological comparisons were made among 11 breeds of Japanese native chickens (Gifujidori, Hinaidori, Shokoku, Totenko, Tomaru, Satsumadori, Shamo, Koshamo, Koeyoshi, Chabo and Nagoya), White Leghorn, broiler chickens (Chunky) and red junglefowl collected in the Philippines, based on results of direct measurements and analysis by computer vision techniques of the skull. 2. Analysis of direct measurements identified two groups of chicken: a small type that included the Chabo, Koshamo, red junglefowl, Gifujidori and Shokoku and a large type that included the remaining breeds studied. These groupings were made based on size determined both in the first (PC1) and second principal component (PC2). The greatest length of the cranium and condylobasal length greatly contributed to the morphological differences between these two groups. 3. Analysis by computer vision techniques, however, identified three groups: the Bantam group (which includes red junglefowl), Shokoku group and Shamo group. White Leghorn clustered within the Shokoku group while the broiler chicken belonged to the Shamo group. The region around the junction of the neural cranium and the visceral cranium contributed greatly to the morphological differences among breeds, both in the PC1 and PC2.
Collapse
Affiliation(s)
- Y Ino
- Faculty of Agriculture, Tokyo University of Agriculture, Kanagawa, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Kashiwagi T, Matsushita T, Ito Y, Hirashima K, Sanda N, Fujimori Y, Yamada T, Okumura K, Takagi A, Murate T, Katsumi A, Takamatsu J, Yamamoto K, Naoe T, Kojima T. L1503R is a member of group I mutation and has dominant-negative effect on secretion of full-length VWF multimers: an analysis of two patients with type 2A von Willebrand disease. Haemophilia 2008; 14:556-63. [PMID: 18397285 DOI: 10.1111/j.1365-2516.2008.01703.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Type 2A von Willebrand disease (VWD) is characterized by decreased platelet-dependent function of von Willebrand factor (VWF); this in turn is associated with an absence of high-molecular-weight multimers. Sequence analysis of the VWF gene from two unrelated type 2A VWD patients showed an identical, novel, heterozygous T-->G transversion at nucleotide 4508, resulting in the substitution of L1503R in the VWF A2 domain. This substitution, which was not found in 60 unrelated normal individuals, was introduced into a full-length VWF cDNA and subsequently expressed in 293T cells. Only trace amount of the mutant VWF protein was secreted but most of the same was retained in 293T cells. Co-transfection experiment of both wild-type and mutant plasmids indicated the dominant-negative mechanism of disease development; as more of mutant DNA was transfected, VWF secretion was impaired in the media, whereas more of VWF was stored in the cell lysates. Molecular dynamic simulations of structural changes induced by L1503R indicated that the mean value of all-atom root-mean-squared-deviation was shifted from those with wild type or another mutation L1503Q that has been reported to be a group II mutation, which is susceptible to ADAMTS13 proteolysis. Protein instability of L1503R may be responsible for its intracellular retention and perhaps the larger VWF multimers, containing more mutant VWF subunits, are likely to be mal-processed and retained within the cell.
Collapse
Affiliation(s)
- T Kashiwagi
- Department of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Okada H, Kunishima S, Hamaguchi M, Takagi A, Yamamoto K, Takamatsu J, Matsushita T, Saito H, Kojima T, Yamazaki T. THE PROTEIN S THROMBIN SENSITIVE REGION CONTRIBUTES REGULATION OF WARFARIN TREATED DES-GAMMA-CARBOXYLATED PROTEIN S SECRETION: A STUDY OF A NOVEL SPLICE SITE MUTATION OF PROTEIN S GENE AND ITS MOLECULAR CONSEQUENCES. J Thromb Haemost 2007. [DOI: 10.1111/j.1538-7836.2007.tb01011.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
12
|
Nonogaki K, Hirooka Y, Itoh A, Kawashima H, Ohmiya N, Niwa Y, Goto H, Yamamoto K, Takamatsu J, Yokokawa K. Combined treatment with immunotherapy and chemotherapy using endoscopic ultrasonography guided injection for locally advanced pancreatic carcinoma. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.13503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
13503 Background: Dendritic cells (DCs) play a pivotal role in T cell-mediated immunity. Usually, mature DCs were cultured using resected tumor tissue, but for inoperable cases, this method is impractical. The injection of immature DCs into the tumor after appropriate chemotherapy is reasonable, if DCs come to maturity capturing the specific cancer antigen . The aim of this study is to assess the toxicity and efficacy of combined treatment with immunotherapy and chemotherapy for locally advanced pancreatic carcinoma. Methods: Five patients with pathologically confirmed pancreatic ductal carcinoma using EUS-FNA were enrolled, median age 56 years (range, 46–70 years). All cases without distant metastasis were diagnosed as surgically unresectable . Patients underwent leukapheresis, immature DCs were prepared from peripheral blood by a culture with granulocyte macrophage colony-stimulating factor and interleukin 4. Lymphokine-activated killer (LAK) were also prepared from peripheral blood. Immature DCs were injected biweekly in the mass by endoscopic ultrasound-guided fine needle injection (EUS-FNI), LAK were administered intravenously. Patients received the treatment of gemcitabine 1000 mg / m2 by intravenous injection 3 days before the immunotherapy. One course with 6 times combined therapy was continued until the judgment of progressive diseases (PD) was given. The toxicity and efficacy of this treatment were assessed. We also assessed whether tumor associated antigen (TAA)-specific IFN-?producing cells increase after treatment. Results: Hematological toxicity occurred in one case, leucopenia of grade 2. No severe toxicities of grade 3 to 4 occurred. One had a partial response (PR), stable disease (SD) was observed in 2 patients for more than 6 months (long-term SD). PR patient could undergo curative operation after this therapy. The number of TAA-specific IFN-?producing cells in PR patient increased 12-fold higher than that seen before treatments. Conclusions: These results support the safety and efficacy of combined treatment with immunotherapy and chemotherapy for locally advanced pancreatic ductal carcinoma. This treatment may be a useful for the treatment of pancreatic ductal carcinoma. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Nonogaki
- G. Shinyokohama Medical Clinic, Yokohama, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; Nagoya University Hospital, Nagoya, Japan; MEDINET Co.,Ltd, Yokohama, Japan; Shinyokohama Medical Clinic,Yokohama,Japan
| | - Y. Hirooka
- G. Shinyokohama Medical Clinic, Yokohama, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; Nagoya University Hospital, Nagoya, Japan; MEDINET Co.,Ltd, Yokohama, Japan; Shinyokohama Medical Clinic,Yokohama,Japan
| | - A. Itoh
- G. Shinyokohama Medical Clinic, Yokohama, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; Nagoya University Hospital, Nagoya, Japan; MEDINET Co.,Ltd, Yokohama, Japan; Shinyokohama Medical Clinic,Yokohama,Japan
| | - H. Kawashima
- G. Shinyokohama Medical Clinic, Yokohama, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; Nagoya University Hospital, Nagoya, Japan; MEDINET Co.,Ltd, Yokohama, Japan; Shinyokohama Medical Clinic,Yokohama,Japan
| | - N. Ohmiya
- G. Shinyokohama Medical Clinic, Yokohama, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; Nagoya University Hospital, Nagoya, Japan; MEDINET Co.,Ltd, Yokohama, Japan; Shinyokohama Medical Clinic,Yokohama,Japan
| | - Y. Niwa
- G. Shinyokohama Medical Clinic, Yokohama, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; Nagoya University Hospital, Nagoya, Japan; MEDINET Co.,Ltd, Yokohama, Japan; Shinyokohama Medical Clinic,Yokohama,Japan
| | - H. Goto
- G. Shinyokohama Medical Clinic, Yokohama, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; Nagoya University Hospital, Nagoya, Japan; MEDINET Co.,Ltd, Yokohama, Japan; Shinyokohama Medical Clinic,Yokohama,Japan
| | - K. Yamamoto
- G. Shinyokohama Medical Clinic, Yokohama, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; Nagoya University Hospital, Nagoya, Japan; MEDINET Co.,Ltd, Yokohama, Japan; Shinyokohama Medical Clinic,Yokohama,Japan
| | - J. Takamatsu
- G. Shinyokohama Medical Clinic, Yokohama, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; Nagoya University Hospital, Nagoya, Japan; MEDINET Co.,Ltd, Yokohama, Japan; Shinyokohama Medical Clinic,Yokohama,Japan
| | - K. Yokokawa
- G. Shinyokohama Medical Clinic, Yokohama, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; Nagoya University Hospital, Nagoya, Japan; MEDINET Co.,Ltd, Yokohama, Japan; Shinyokohama Medical Clinic,Yokohama,Japan
| |
Collapse
|
13
|
Yamamoto K, Kojima T, Takeshita K, Matsushita T, Takamatsu J. Pitavastatin attenuates the upregulation of tissue factor in restraint-stressed mice. Thromb Res 2007; 120:143-4. [PMID: 17011613 DOI: 10.1016/j.thromres.2006.07.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2006] [Revised: 06/30/2006] [Accepted: 07/11/2006] [Indexed: 11/21/2022]
|
14
|
Okada H, Yamazaki T, Takagi A, Murate T, Yamamoto K, Takamatsu J, Matsushita T, Naoe T, Kunishima S, Hamaguchi M, Saito H, Kojima T. In vitro characterization of missense mutations associated with quantitative protein S deficiency. J Thromb Haemost 2006; 4:2003-9. [PMID: 16961607 DOI: 10.1111/j.1538-7836.2006.02061.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE To elucidate the molecular consequences of hereditary protein S (PS) deficiency, we investigated the in vitro synthesis of the PS missense mutants in COS-1 cells and their activated protein C (APC) cofactor activities. PATIENTS Four patients with quantitative PS deficiency suffering from venous thrombosis were examined. RESULTS We identified three distinct novel missense mutations, R275C, P375Q and D455Y, and two previously reported missense mutations, C80Y and R314H. The P375Q and D455Y mutations were found in one patient and observed to be in linkage on the same allele. The R314H mutant showed the lowest level of expression (32.7%), and the C80Y, P375Q + D455Y, and R275C mutants exhibited a moderate impairment of expression, that is, 43.8%, 49.5%, and 72.3% of the wild type, respectively. Furthermore, pulse-chase experiments demonstrated that all mutants showed impaired secretion and longer half-lives in the cells than the wild type PS. In the APC cofactor assays, the C80Y mutant showed no cofactor activity, and the R275C mutant showed reduced activity, 62.3% of the wild type PS, whereas the R314H and P375Q + D455Y mutants exhibited normal cofactor activity. CONCLUSION These data indicate that the C80Y and R275C mutations affect the secretion and function of the PS molecule, and that the R314H and P375Q + D455Y mutations are responsible for only secretion defects, causing the phenotype of quantitative PS deficiency observed in the patients.
Collapse
Affiliation(s)
- H Okada
- Department of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Yoshioka A, Fukutake K, Takamatsu J, Shirahata A. Clinical Evaluation of Recombinant Factor VIII Preparation (Kogenate) in Previously Treated Patients with Hemophilia A: Descriptive Meta-Analysis of Post-Marketing Study Data. Int J Hematol 2006; 84:158-65. [PMID: 16926139 DOI: 10.1532/ijh97.06019] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The safety and efficacy of Kogenate, a recombinant factor VIII (rFVIII) preparation for the treatment of bleeding episodes, were studied in a 123-patient meta-analysis population of previously treated patients (PTPs), including 15 enrolled in the registration Phase III trial (PTP-I group), 93 from the post-marketing special investigation (PTP-II group), and 15 from short-term special investigations in surgery or tooth extraction (SI group). These patients (82 severe, 31 moderate, 9 mild, and 1 unknown), aged 11 months to 72 years, were enrolled in 28 centers in Japan. Blood samples taken at the baseline and at 3, 6, 9, 12, 18, and 24 months after the introduction of Kogenate were evaluated for FVIII inhibitor antibodies, antibodies formed against trace proteins derived from the rFVIII production process, and for general changes in laboratory test results. Mean exposure to Kogenate was 1103 days in PTP-I, 86 days in PTP-II, 27 days in patients in surgery, and 2 days in patients with tooth extraction. Assessment of FVIII inhibitor activity was conducted in 115 of the 123 patients by means of the Bethesda assay. Twelve patients were found to have a low titer of FVIII inhibitor (0.5-3.0 BU/mL) prior to any administration of Kogenate, and 103 were inhibitor-negative at the baseline. Among this latter group, 3 patients (2.9%) tested inhibitor-positive, with titers ranging from 1.2 to 2.1 BU/mL, with 4 patients below 1.0 BU/mL. One patient in the 11 PTPs investigated (PTP-I) developed antibodies against baby hamster kidney protein and mouse immunoglobulin G, but these findings were transient and asymptomatic. Hemostasis was achieved (markedly effective or effective) in 3666 of the 3855 bleeding episodes (95.1%) observed in 108 patients. Only 1 infusion was necessary in 3790 (98.3%) of these episodes. These data indicate that Kogenate is safe and very effective for the treatment of bleeding in PTPs with hemophilia A.
Collapse
Affiliation(s)
- A Yoshioka
- Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan.
| | | | | | | |
Collapse
|
16
|
Hiraiwa T, Ito M, Imagawa A, Takamatsu J, Kuma K, Miyauchi A, Hanafusa T. Restriction of dietary Iodine does not ameliorate the early effect of anti-thyroid drug therapy for Graves' disease in an area of excessive iodine intake. J Endocrinol Invest 2006; 29:380-4. [PMID: 16699308 DOI: 10.1007/bf03344113] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The close relationship between iodine intake and the effects of anti-thyroid drugs (ATD) for Graves' disease (GD) has been well established. However, it remains unknown whether restriction of dietary iodine improves the effect of ATD. This study aimed to clarify this issue in Japanese patients with GD who routinely ingest large amounts of dietary iodine. We performed a prospective clinical study in 81 patients with newly diagnosed GD who were divided into an iodine restricted group and a control group. Urinary iodine, thyroid hormones and TSH receptor antibody were measured during the first 8 weeks of ATD therapy. Urinary iodine concentrations in the iodine restricted group were significantly lower than in the control group (p=0.043). However, there were no significant differences in the decrease of thyroid hormones and TSH receptor antibody between the two groups. Restriction of dietary iodine does not ameliorate the effect of ATD therapy for GD in an area of excessive iodine intake.
Collapse
Affiliation(s)
- T Hiraiwa
- First Department of Medicine, Osaka Medical College, Takatsuki city, Japan.
| | | | | | | | | | | | | |
Collapse
|
17
|
Yamakage N, Ikejiri M, Okumura K, Takagi A, Murate T, Matushita T, Naoe T, Yamamoto K, Takamatsu J, Yamazaki T, Hamaguchi M, Kojima T. A case of coagulation factor V deficiency caused by compound heterozygous mutations in the factor V gene. Haemophilia 2006; 12:172-8. [PMID: 16476093 DOI: 10.1111/j.1365-2516.2006.01206.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
We investigated the molecular basis of a severe factor V (FV) deficiency in a Japanese female, and identified two distinct mutations in the FV gene, a novel cytosine insertion (1943insC) and a previously reported point mutation (A5279G). We expected the patient to be a compound heterozygote for those mutations, as a 1943insC, but not an A5279G, was found in the mother and a sibling. The 1943insC will cause a frame-shift after 590Gln, resulting in amino acid substitutions with two abnormal residues followed by a stop codon in the FV A2 domain (FS592X). The A5279G will cause an amino acid alteration in the FV A3 domain (Y1702C), which has been observed in several ethnic groups. We found that both mutant mRNAs were detected by reverse transcriptase polymerase chain reaction (RT-PCR) in the patient's platelets, whereas no FV antigen and activity were detected in plasma. On the one hand, the RT-PCR signal from the FS592X-FV mutant mRNA was markedly reduced, suggesting that the RNA surveillance system would eliminate most of the abnormal FS592X-FV transcripts with a premature termination. On the other hand, expression analyses revealed that only small amounts of Y1702C-FV with a low specific activity were secreted, and that the FS592X-FV was not detected in cultured media. These data indicated that both mutant FV molecules would be impaired, at least in part, during the post-transcriptional process of protein synthesis and/or in secretion. Taken together, it seems to suggest that each gene mutation could be separately responsible for severe FV deficiency, while this phenotype is due to the in-trans combination of the two defects.
Collapse
Affiliation(s)
- N Yamakage
- Department of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, and Division of Transfusion Medicine, Nagoya University Hospital, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Yamamoto K, Honda T, Matsushita T, Kojima T, Takamatsu J. Anti-HCV agent, ribavirin, elevates the activity of clotting factor VII in patients with hemophilia: a possible mechanism of decreased events of bleeding in patients with hemophilia by ribavirin. J Thromb Haemost 2006; 4:469-70. [PMID: 16420581 DOI: 10.1111/j.1538-7836.2006.01761.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
19
|
|
20
|
Toyoda H, Honda T, Katano Y, Goto H, Takamatsu J. Clearance of GB virus C during highly active antiretroviral therapy and course of HIV disease progression in HIV-infected patients with hemophilia. Eur J Clin Microbiol Infect Dis 2005; 24:645-6. [PMID: 16200339 DOI: 10.1007/s10096-005-0020-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- H Toyoda
- Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
| | | | | | | | | |
Collapse
|
21
|
Yamamoto K, Kojima T, Adachi T, Hayashi M, Matsushita T, Takamatsu J, Loskutoff DJ, Saito H. Obesity enhances the induction of plasminogen activator inhibitor-1 by restraint stress: a possible mechanism of stress-induced renal fibrin deposition in obese mice. J Thromb Haemost 2005; 3:1495-502. [PMID: 15978107 DOI: 10.1111/j.1538-7836.2005.01399.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND AND OBJECTIVES Cardiovascular/thrombotic diseases are frequently induced by a variety of stressors. Obese patients are susceptible to thrombotic diseases associated with stress, but the underlying mechanism is still unknown. We have begun to investigate the expression of a primary inhibitor of fibrinolysis, plasminogen activator inhibitor-1 (PAI-1), in association with tissue thrombosis, using restraint-stressed obese mice. METHODS AND RESULTS We analyzed the expression of PAI-1 after restraint (immobilization) stress in genetically obese mice in comparison with their lean counterparts. Dramatic increases in PAI-1 antigen in plasma and in tissue extracts were observed in the obese mice exposed to restraint stress. The induction of PAI-1 mRNA by stress in the tissues was also pronounced in the stressed obese mice as compared with the lean mice, especially in the hearts and adipose tissues. In situ hybridization analysis revealed that strong signals for PAI-1 mRNA were localized in the adipocytes, cardiovascular endothelial cells, and renal glomerular cells of the stressed obese mice. Histological examination revealed that renal glomerular fibrin deposition was detected only in the obese mice after 2 h of restraint stress. CONCLUSIONS Obesity enhances the stress-mediated PAI-1 induction in the blood and tissues. This phenomenon may be associated with the increased risk of stress-induced renal fibrin deposition in obese subjects.
Collapse
Affiliation(s)
- K Yamamoto
- Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Yoshioka A, Fukutake K, Takamatsu J, Shirahata A. Clinical Evaluation of a Recombinant Factor VIII Preparation (Kogenate) in Previously Untreated Patients with Hemophilia A. Int J Hematol 2003; 78:467-74. [PMID: 14704043 DOI: 10.1007/bf02983823] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
The safety and efficacy of a recombinant factor VIII (rFVIII) preparation (Kogenate) for the treatment of bleeding episodes was studied in previously untreated patients (PUPs) with severe, moderate, and mild hemophilia A. Patient peripheral blood samples taken at baseline and at 3, 6, 9, 12, 18, and 24 months after the first infusion were evaluated for FVIII inhibitor antibodies by the Bethesda assay, for antibodies formed against trace proteins derived from the rFVIII production process, and for general changes in laboratory test results. Samples for general laboratory testing were also drawn every 6 months after the first 24 months. Hemostatic efficacy was assessed by physicians, and adverse events were recorded throughout the study period. Forty-three PUPs (30 with FVIII:C <1%; 10 with FVIII:C 1%-5%; and 3 with FVIII:C >5%) aged 3 months to 32 years were enrolled at 33 centers in Japan. Patients were studied for a mean of 51 months (range, 11-80 months), and the mean exposure time was 83 days (range, 2-571 days). The incidence of occurrence of FVIII inhibitors was 34.9% (high responders [> or = 10 Bethesda U/mL], 11.6%; low responders [0.5-<10 Bethesda U/mL], 23.3%). The median cumulative exposure time of inhibitor detection was 12 days, indicating inhibitor development at an early stage after the start of infusion of this preparation. Hemostasis was achieved with a single dose of Kogenate in 94.8% of the 951 bleeding episodes recorded in the study. Transient increases in antibodies against baby hamster kidney proteins and antimouse immunoglobulin G were observed in 14.0% and 18.6% of patients, respectively. Anti-rFVIII seroconversion was observed in 18.6% of patients and only in patients with inhibitor antibodies. Antibody responses to trace proteins were not correlated with drug-related adverse events with the exception of FVIII activity inhibition in PUPs with anti-rFVIII seroconversion. These data indicate that Kogenate is safe and effective for the treatment of bleeding in PUPs with hemophilia A.
Collapse
Affiliation(s)
- A Yoshioka
- Department of Pediatrics, Nara Medical University, Kashihara, Japan.
| | | | | | | |
Collapse
|
23
|
Ishizuka K, Kimura T, Yoshitake J, Akaike T, Shono M, Takamatsu J, Katsuragi S, Kitamura T, Miyakawa T. Possible assessment for antioxidant capacity in Alzheimer's disease by measuring lymphocyte heme oxygenase-1 expression with real-time RT-PCR. Ann N Y Acad Sci 2002; 977:173-8. [PMID: 12480749 DOI: 10.1111/j.1749-6632.2002.tb04814.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- K Ishizuka
- Department of Neuropsychiatry, Kumamoto University School of Medicine, 1-1-1 Honjo, Kumamoto 860-8556, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Takamatsu J, Toyoda H, Fukuda Y, Nakano I, Yokozaki S, Hayashi K, Saito H. Effects of HAART on hepatitis C, hepatitis G, and TT virus in multiply coinfected HIV-positive patients with haemophilia. Haemophilia 2001; 7:575-81. [PMID: 11851756 DOI: 10.1046/j.1365-2516.2001.00567.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
In multiply coinfected human immunodeficiency virus (HIV)-positive patients, we investigated the effects of high-activity antiretroviral therapy (HAART) using HIV protease inhibitors on three other viruses: hepatitis C virus (HCV), hepatitis G virus (HGV), and TT virus (TTV). Viral concentrations were measured serially by polymerase chain reaction methods in five patients with quadruple infection (HIV, HCV, HGV, and TTV) and in two patients with triple infection (HIV, HCV, and HGV) before and during HAART. In addition, CD4+ cell counts and serum alanine aminotransferase (ALT) levels were measured serially. Generally we observed no difference in serum HCV RNA, HGV RNA, or TTV DNA concentrations between samples obtained before and after initiation of HAART, whereas HIV RNA concentration decreased and CD4 counts increased in most patients. However, two patients had markedly decreased concentrations of HCV RNA and HGV RNA, respectively, more than 12 months after beginning HAART. Normalization of serum ALT levels was observed in a patient with decline of HCV RNA concentrations. No interactions were observed among these four viruses. HAART had no apparent direct effects on HCV, HGV, or TTV. Further studies will be required to elucidate whether the restoration of immune status through suppression of HIV replication by HAART may affect HCV or HGV RNA concentrations.
Collapse
Affiliation(s)
- J Takamatsu
- Department of Transfusion Medicine, Nagoya University School of Medicine, Nagoya, Japan
| | | | | | | | | | | | | |
Collapse
|
25
|
Toyoda H, Fukuda Y, Nakano I, Katano Y, Yokozaki S, Hayashi K, Ito Y, Suzuki K, Nakano H, Saito H, Takamatsu J. TT virus genotype changes frequently in multiply transfused patients with hemophilia but rarely in patients with chronic hepatitis C and in healthy subjects. Transfusion 2001; 41:1130-5. [PMID: 11552070 DOI: 10.1046/j.1537-2995.2001.41091130.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND TT virus (TTV), a novel DNA virus, was originally thought to be transmitted by transfusion. However, nonparenteral transmission is recently suspected to be a major mode of transmission. To investigate the possibility of reinfection with TTV in multiply transfused patients and to evaluate the significance of transfusion transmission of TTV in patients with hemophilia, serial changes in TTV genotype were investigated in three groups. STUDY DESIGN AND METHODS Serial changes in TTV genotype were investigated in 16 multiply transfused patients with hemophilia, 16 age-matched patients with chronic hepatitis C, and 16 age-matched healthy subjects. RESULTS Mixed infection with multiple TTV genotypes was common in all groups. However, changes in TTV genotype were frequent in patients with hemophilia (15/16; 93.8%) but rare in patients with chronic hepatitis C and in healthy subjects (each group: 1/16; 6.3%). CONCLUSION Changes in TTV genotype were frequently observed in multiply transfused patients with hemophilia but not in patients with chronic hepatitis or in healthy subjects without risk of transfusion transmission. This difference may suggest that exposure to TTV or even reinfection occurs frequently in patients with hemophilia, which could be evidence of transfusion transmission of TTV in this population.
Collapse
Affiliation(s)
- H Toyoda
- Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Amano K, Katsuragi S, Takamatsu J, Ogata A, Miyazaki C, Deshimaru M, Miyakawa T. Differences between the tolerance characteristics of two anticonvulsant benzodiazepines in the amygdaloid-kindled rat. Life Sci 2001; 69:1049-55. [PMID: 11508647 DOI: 10.1016/s0024-3205(01)01187-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The characteristics of the development of tolerance to the anticonvulsant effects of chronic treatment by dipotassium clorazepate and diazepam using amygdaloid-kindled rats were investigated. Dipotassium clorazepate (5 mg/kg) or diazepam (5 mg/kg) were intraperitoneally administered for 10 consecutive days. Tolerance to the anticonvulsant effect of dipotassium clorazepate developed in seizure stage on day 6, after-discharge duration on day 7 and seizure latency on day 4. In contrast, tolerance to the effects of diazepam developed more rapidly in seizure stage on day 4, after-discharge duration on day 4 and seizure latency on day 3. Thus tolerance to the anticonvulsive effect of dipotassium clorazepate developed relatively slower than that to diazepam. All rats had stage 5 convulsions 24 hr after cessation of the administration of dipotassium clorazepate and diazepam. Concomitant determinations of plasma concentrations of the main metabolite of dipotassium clorazepate and diazepam, desmethyldiazepam, showed no statistical difference during treatment, suggesting that the developed tolerance was not metabolic but functional.
Collapse
Affiliation(s)
- K Amano
- Department of Psychiatry, Kikuchi National Hospital, Kumamoto, Japan
| | | | | | | | | | | | | |
Collapse
|
27
|
Okudaira M, Tsuda F, Ikawa N, Takamatsu J, Tokudome S, Kurosu K, Mayumi M. Hepatic histopathologic range compared with virological studies of hepatitis viruses among autopsy cases in Tokyo. Hepatol Res 2001; 20:320-334. [PMID: 11404192 DOI: 10.1016/s1386-6346(01)00078-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Few reports exist comparing virological studies on hepatitis viruses with histopathological studies of autopsy cases other than those of liver clinics. Relations between hepatitis virus-related markers and hepatic histopathology were studied in 1044 autopsy cases (779 men and 265 women) at the Medical Examiner's Office, Tokyo. Heart blood was obtained at the autopsy, and the sera were submitted for virus-marker detection of HBV, HCV, and HGV/GBV-C. Hematoxylin and eosin-stained paraffin sections were used for histological assessment. Histopathologically, 463 cases were determined as so-called normal liver; among them 440 cases (95.0%) were negative for all hepatitis virus-related markers, but HBV-DNA was positive in 13 cases, three cases were positive for HCV-RNA (indicating a healthy carrier rate of HCV-RNA of 4.1%), and seven cases were positive for HGV/GBV-C RNA. The incidence of these three virus-related markers was low in cases with fatty liver and micronodular cirrhosis, but in cases with chronic hepatitis, macronodular cirrhosis and hepatocellular carcinoma, the incidence of HBV-DNA and HCV-RNA increased with advancing disease. A positive rate of anti-HBs or anti-HBc (HBV-Ab) or both was found between 30 and 50% in all histopathological groups, and no noticeable relations between the positive rate and microscopical changes were detected. The presence of HGV/GBV-C RNA seemed to be unrelated to hepatic inflammation or generalized inflammatory changes or both occurring together. The decadal age incidence of the virus-related markers and their incidence in various hepatic diseases are also reported.
Collapse
Affiliation(s)
- M Okudaira
- Japan Bioassay Research Center, Japan Industrial Safety and Health Association, 2445 Hirasawa, Hadano, 257-0015, Kanagawa, Japan
| | | | | | | | | | | | | |
Collapse
|
28
|
Shirahata A, Kamiya T, Takamatsu J, Kojima T, Fukutake K, Arai M, Hanabusa H, Tagami H, Yoshioka A, Shima GM, Naka GH, Fujita GS, Minamoto Y, Kamizono J, Saito H. Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with hemophilia with inhibitors. Int J Hematol 2001; 73:517-25. [PMID: 11503968 DOI: 10.1007/bf02994016] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
A multicenter and open-labeled clinical trial of human recombinant factor VIIa (rFVIIa) was conducted in Japanese patients with severe hemophilia A or B with inhibitors. The trial consisted of 2 parts. In study 1, the pharmacokinetics, pharmacodynamics, and safety of a single dose of 120 microg/kg of rFVIIa were investigated in 8 patients. In the subsequent study 2, the hemostatic effect and safety of rFVIIa were evaluated during a 24-week period in 10 patients. In study 1, the mean maximum FVII-coagulant activity (FVII:C) was found to occur after 10 minutes; activity then decreased rapidly and returned to the baseline within 24 hours after a single intravenous infusion of rFVIIa. The mean half-life of FVII:C was 3.5 hours. The activated partial thromboplastin time and prothrombin time in the patients were immediately shortened but returned to the baseline within 24 hours after dosing. In study 2, 86 microg/kg to 120 microg/kg of rFVIIa (mean, 97 microg/kg) was administered 1 to 85 times to 10 patients. A total of 58.0% (91/157) of bleeding episodes were treated excellently or effectively, with 5 (3.2%) ineffective episodes. There was no apparent trend in the relationship of the hemostatic effect with bleeding sites, mean dose, or number of injections. The efficacy rate, however, was significantly higher (90.0%) in bleeding episodes treated within 3 hours than in those treated at longer intervals (31.0%). No treatment-related adverse events were observed, and there was no evidence of antibody formation to rFVIIa. In conclusion. rFVIIa is an effective and well-tolerated option for treatment of bleeding episodes in hemophilia patients with inhibitors.
Collapse
Affiliation(s)
- A Shirahata
- Department of Pediatrics, University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Yoshioka A, Shima M, Fukutake K, Takamatsu J, Shirahata A. Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: a long-term, multicentre clinical study in Japan. Haemophilia 2001; 7:242-9. [PMID: 11380627 DOI: 10.1046/j.1365-2516.2001.00511.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The recombinant full-length FVIII product Kogenate has been reformulated using sucrose (rFVIII-FS) instead of human serum albumin as a stabiliser in purification and formulation. The in vivo recovery, haemostatic efficacy, and safety of rFVIII-FS were investigated in 20 previously treated patients with severe or moderate haemophilia A for > or = 24 weeks. In vivo recoveries of 73.5 +/- 16.3%, 78.4 +/- 16.1%, and 82.8 +/- 23.9% after the initial infusion of 50 IU kg(-1) rFVIII-FS and at weeks 12 and 24, respectively, showed no significant changes over time. A total of 1115 infusions (mean dose 24.1 +/- 8.4 IU kg(-1)) were included in the analysis of haemostatic efficacy. One (80.5%) or two (8.2%) infusions achieved adequate haemostasis in 88.7% of all bleeding episodes, and haemostatic efficacy was judged 'excellent' or 'good' in 749 of 764 episodes (98.0%). The haemostatic efficacy was judged as 'excellent' or 'good' in 924 of 1115 (82.9%) infusions. Twenty-one adverse events were observed in 12 patients in the total 1541 infusions included in the safety analysis. Causality with respect to rFVIII-FS could not be ruled out in three events in one HIV-negative patient: elevated CD4(%), decreased CD8(%), and elevated CD4/CD8 ratio. No FVIII inhibitor development was observed in any patient. ELISA assay testing for antibodies to rFVIII, baby hamster kidney cell (BHK) protein, and murine IgG were all negative. These results show that rFVIII-FS is a safe and effective for long-term treatment of patients with haemophilia A.
Collapse
Affiliation(s)
- A Yoshioka
- Department of Paediatrics, Nara Medical University, Kashihara, Nara, Japan
| | | | | | | | | |
Collapse
|
30
|
Arai T, Ikeda K, Akiyama H, Tsuchiya K, Yagishita S, Takamatsu J. Intracellular processing of aggregated tau differs between corticobasal degeneration and progressive supranuclear palsy. Neuroreport 2001; 12:935-8. [PMID: 11303763 DOI: 10.1097/00001756-200104170-00014] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) are sporadic neurodegenerative diseases with intracytoplasmic aggregates of the microtubule-associated protein, tau, in neurons and glial cells. Immunoblot analysis of detergent-insoluble brain extracts of patients with CBD and PSP shows distinctive patterns of tau fragments. These results suggest differing intracellular processing of aggregated tau in these two diseases despite an identical composition of tau isoforms. Such biochemical differences may be related to the neuropathological features of these diseases.
Collapse
Affiliation(s)
- T Arai
- Department of Neuropathology, Tokyo Institute of Psychiatry, Japan
| | | | | | | | | | | |
Collapse
|
31
|
Nakasone T, Takamatsu J, Watanabe K, Naganawa S, Somey K, Yoshino N, Kaizu M, Ohsu T, Takizawa M, Izumi Y, Kawahara M, Hara T, Fujimura Y, Yamada K, Nagai Y, Yamazaki S, Honda M. Decline in the HIV-1 isolation rate in Japan: a 12-year observation. Microbiol Immunol 2001; 44:949-52. [PMID: 11145277 DOI: 10.1111/j.1348-0421.2000.tb02588.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Since 1988, we have isolated HIV-1 from 614 HIV-1-infected persons (total sample=2,785) in Japan. During the past 12 years, we have found a decline in the HIV-1 isolation rate in Japan, with two identifiable turning points, 1991-1992 and 1996-1997. The two turning points correspond to shifts in anti-HIV-1 therapy. These findings suggest that HIV-1 in Japan is currently biologically well controlled, probably due to anti-HIV-1 therapy. On the other hand, this decline is inconsistent with the recent increase of genetic drug-resistant HIV-1 in Japan. Further studies are needed to clarify mechanisms that might explain the discrepancy.
Collapse
Affiliation(s)
- T Nakasone
- Vaccine Research and Development Group, AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Toyoda H, Fukuda Y, Yokozaki S, Hayashi K, Saito H, Takamatsu J. Safety and complications of interventional radiology for hepatocellular carcinoma in patients with haemophilia and cirrhosis. Br J Haematol 2001; 112:1071-3. [PMID: 11298608 DOI: 10.1046/j.1365-2141.2001.02606.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Many patients with haemophilia have been chronically infected with hepatitis virus owing to multiple transfusions and the prevalence of hepatocellular carcinoma will probably increase in this population. We evaluated the safety and complications of radiological intervention for hepatocellular carcinoma in eight patients with haemophilia and cirrhosis. Radiological interventions can be performed safely in all patients with haemophilia. Unexpectedly, the most common complication was bleeding from the gastrointestinal tract. Attention should be paid to this potential problem in order to take appropriate steps to minimize its occurrence.
Collapse
Affiliation(s)
- H Toyoda
- Second Department of Internal Medicine, Nagoya University School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya,466-8550, Japan.
| | | | | | | | | | | |
Collapse
|
33
|
Isotani H, Sanda K, Kameoka K, Takamatsu J. McCune-Albright syndrome associated with non-autoimmune type of hyperthyroidism with development of thyrotoxic crisis. Horm Res 2001; 53:256-9. [PMID: 11150888 DOI: 10.1159/000023576] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
We report on a patient having McCune-Albright syndrome (MAS) associated with non-autoimmune hyperthyroidism associated with thyrotoxic crisis. Polyostotic fibrous dysplasia developed at age 8, and café-au-lait pigmentation was noted on the skin. At age 18, he developed hyperthyroidism with multiple adenomatous changes. The hyperthyroidism had been controlled with an antithyroid drug, but the antithyroid medication was discontinued by the patient at age 23. One year later, thyrotoxic crisis developed with fever, convulsions and loss of consciousness. Thyroid function tests showed serum concentrations of free T(4) of 5.1 ng/dl, and serum TSH of <0.1 microU/ml. Serum thyroglobulin concentrations were markedly increased (1,280 ng/ml). Three major thyroid-related autoantibodies (TSH receptor antibody, antithyroglobulin, and antimicrosomal antibodies) were not detected in serum. Serum GH concentrations were increased, and not suppressed by the glucose tolerance test, but increased paradoxically by TRH. The thyrotoxic crisis was ameliorated by treatment with a beta-adrenergic receptor-blocking agent, glucocoroticoid, iodine, antithyroid drug, and antibiotics. The cause of thyroidal defect in our patient is not considered to be autoimmune hyperthyroidism, but hyperthyroidism due to constitutive activation of G(s)alpha by inhibition of its GTPase. This paper describes, as far as we know, the first case of MAS associated with thyrotoxic crisis. Because hyperthyroidism in this patient recurred quickly after discontinuation of the antithyroid drug, the mode of treatment for MAS-associated hyperthyroidism appears to be total surgical ablation or repetitive radioiodine therapy.
Collapse
Affiliation(s)
- H Isotani
- Department of Internal Medicine, Hirakata City Hospital, Hirakata, Japan.
| | | | | | | |
Collapse
|
34
|
Abstract
The aetiology of rapidly destructive arthropathy is still being debated. We report a 48-year-old male haemophiliac who exhibited hip arthropathy that was similar to rapidly destructive arthropathy. The hip joint was destroyed 6 months after the onset of symptoms. Results of clinical and laboratory examinations did not show any features of neuropathic, inflammatory or septic arthropathy, except for coagulopathy. Magnetic resonance imaging revealed an expansive joint capsule with synovial proliferation in the affected hip joint. Total hip arthroplasty was carried out successfully with total resection of the synovial tissue and joint capsule. A histological examination revealed bone necrosis, nonspecific inflammation, haemosiderosis and synovial hypertrophy. The recurrent bleeding into the hip joint induced pronounced inflammation with synovial proliferation and acute destruction of bony tissue.
Collapse
Affiliation(s)
- N Ishiguro
- Department of Orthopedic Surgery, Department of Blood Transfusion Service, Nagoya University, Japan
| | | | | | | | | | | |
Collapse
|
35
|
Hayashi K, Fukuda Y, Nakano I, Katano Y, Nagano K, Yokozaki S, Hayakawa T, Toyoda H, Takamatsu J. Infection of hepatitis A virus in Japanese haemophiliacs. J Infect 2001; 42:57-60. [PMID: 11243755 DOI: 10.1053/jinf.2000.0781] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
OBJECTIVES Outbreaks of hepatitis A virus (HAV) infection in haemophiliacs have been reported from many countries. The aim of this study was to determine the prevalence of hepatitis A virus antibody (HAVAb) in Japanese haemophiliacs. METHODS Sixty-seven male haemophiliacs were recruited for this study of HAV infection. We also compared the rate of HAV infection with that of human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis G virus (HGV). RESULTS Fifteen of 67 haemophiliacs (22.4%) were positive for HAVAb. Prevalence of HAVAb was significantly higher in haemophiliacs than in Japanese normal subjects previously reported (P= 0.0001). Age, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin and prevalence of HIV, HCV, and HGV were not statistically different between HAVAb positive and HAVAb negative haemophiliacs. We suggest that the use of clotting factor concentrates is closely associated with HAV infection, but HAV infection does not have an effect on clinical course. CONCLUSIONS Administration of clotting factor concentrates may increase risk of HAV infection in haemophiliacs.
Collapse
Affiliation(s)
- K Hayashi
- Second Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Iwaki T, Mastushita T, Kobayashi T, Yamamoto Y, Nomura Y, Kagami K, Nakayama T, Sugiura I, Kojima T, Takamatsu J, Kanayama N, Saito H. DNA Sequence Analysis of Protein S Deficiency-Identification of Four Point Mutations in Twelve Japanese Subjects. Semin Thromb Hemost 2001; 27:155-60. [PMID: 11372770 DOI: 10.1055/s-2001-14075] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
The molecular basis for the hereditary type I protein S (PS) deficiency was investigated. DNA sequence analysis of 12 patients with PS deficiency in Japan identified four point mutations and three of them were novel. Nonsense mutations found in two unrelated patients resulted in termination of the PS polypeptide chains at Gln 238 and Lys 392, respectively. Two novel missense mutations were also found in two other patients substituting Asp 202 for Asn and Leu 298 for Pro, respectively. Comparison of the PS amino acid sequences from several mammalians indicated that Asp 202 and Leu 298 were preserved and thus appeared to be responsible for the pathogenesis of PS deficiency.
Collapse
Affiliation(s)
- T Iwaki
- Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Yokozaki S, Takamatsu J, Nakano I, Katano Y, Toyoda H, Hayashi K, Hayakawa T, Fukuda Y. Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy. Blood 2000; 96:4293-9. [PMID: 11110704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023] Open
Abstract
Infection with hepatitis C virus (HCV) or human immunodeficiency virus (HIV) or both is common in hemophiliac patients due to putative transmission through clotting factor concentrates. Recently, highly active antiretroviral therapy (HAART) has been found to markedly improve viremia and immunologic parameters in patients infected with HIV. This report considers interactions between these viral infections, the immune system, and antiretroviral therapy. A total of 130 male hemophiliac patients were grouped according to type of viremia (HCV, HIV, both, or neither). Along with 30 healthy men age-matched to viremic patients, these groups were compared with respect to viral load and immunologic parameters. Thirty-five patients treated as above for HIV were serially followed up. HCV infection was associated with reduced peripheral B-cell and CD4(+)-cell counts and with increased serum IgG and IgM levels, whereas HIV infection was associated with reduced peripheral CD4(+)-cell counts and increased serum IgG and IgA levels. In patients with both viruses, HCV and HIV RNA load correlated inversely with peripheral B-cell and CD4(+)-cell counts, respectively. HAART reduced levels of both viruses in the blood. Of the 25 patients with both viruses, HAART eliminated HCV in 2. In conclusion, immunologic dynamics differed between hemophiliac patients infected with HCV, HIV, or both. The relative dynamics of HCV viral load, peripheral B-cell count, and serum IgM level were similar to those of HIV viral load, CD4(+)-cell count, and serum IgA. (Blood. 2000;96:4293-4299)
Collapse
Affiliation(s)
- S Yokozaki
- Second Department of Internal Medicine, Nagoya University, School of Medicine, Nagoya, Japan
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Hayashi K, Fukuda Y, Nakano I, Katano Y, Yokozaki S, Toyoda H, Takamatsu J, Hayakawa T. Poor response to interferon treatment for chronic hepatitis C in human immunodeficiency virus-infected haemophiliacs. Haemophilia 2000; 6:677-81. [PMID: 11122395 DOI: 10.1046/j.1365-2516.2000.00444.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
We performed a pilot study to evaluate the factors associated with response to interferon (IFN) therapy for chronic hepatitis C (CHC) with human immunodeficiency virus (HIV) coinfected haemophiliacs. Seven haemophiliacs, coinfected with HIV and hepatitis C virus (HCV), received 9 mega-units (MU) of natural IFN-alpha daily during the first 2 weeks and then three times a week for 22 weeks, all injected subcutaneously. Six patients were receiving zidovudine (AZT) 600 mg day-1 and didanosine (ddI) 200 mg day(-1) during IFN therapy. This treatment was safe and well tolerated. Four patients had no detectable serum HCV-RNA at the end of therapy, but long-term, none of the seven patients achieved a sustained response, i.e. undetectable serum HCV-RNA with persistently normal serum alanine aminotransferase (ALT) 6 months after therapy. IFN did not affect CD4-positive cell counts. Most of our patients had high HCV-RNA loads and/or low CD4 counts, both unfavourable markers for IFN therapy. In conclusion, IFN therapy did not eradicate HCV from haemophiliacs coinfected with HIV.
Collapse
Affiliation(s)
- K Hayashi
- Second Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Toyoda H, Fukuda Y, Nakano I, Katano Y, Ebata M, Nagano K, Morita K, Yokozaki S, Takeuchi M, Hayakawa T, Takamatsu J. Massive bleeding from a gastric erosion after transcatheter arterial chemoembolization for hepatocellular carcinoma in a patient with mild haemophilia A. Haemophilia 2000; 6:688-92. [PMID: 11122397 DOI: 10.1046/j.1365-2516.2000.00414.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
We observed massive bleeding from a gastric erosion following transcatheter arterial chemoembolization (TAE) in a patient with mild haemophilia A. A 78-year-old haemophiliac (factor VIII level over 60%) received TAE with farmorubicin and spongel. Haematemesis and melena with loss of consciousness occurred 3 days [corrected] after TAE, and endoscopy revealed superficial erosions with oozing. Toxic effects of the anticancer drug in conjunction with the bleeding disorder may have caused the massive bleeding. We should always consider the possibility of unexpected complications in patients with bleeding disorders; gastrointestinal bleeding can develop during treatment for liver tumours.
Collapse
Affiliation(s)
- H Toyoda
- Second Department of Internal Medicine, Nagoya University School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, 466-8550 Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Yamada M, Fukuda Y, Nakano I, Katano Y, Takamatsu J, Hayakawa T. Serum hyaluronan as a marker of liver fibrosis in hemophiliacs with hepatitis C virus-associated chronic liver disease. Acta Haematol 2000; 99:212-6. [PMID: 9644299 DOI: 10.1159/000040841] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
We measured serum type III procollagen peptide, type IV collagen (IV-C), and hyaluronan (HA) in 36 hemophiliacs with hepatitis C virus (HCV)-related chronic liver disease. We also measured these markers in 19 interferon (IFN)-treated patients before and after a 6-month course of IFN-alpha. The serum concentrations of IV-C and HA were correlated with the stage of fibrosis (IV-C r = 0.38; HA r = 0.78). These markers fell only in complete responders showing sustained clearance of serum HCV RNA by IFN. These results suggest that, in hemophiliacs with chronic liver disease, serum HA measurement might be an alternative to liver biopsy and reflect the response to IFN.
Collapse
Affiliation(s)
- M Yamada
- Second Department of Internal Medicine, Nagoya University School of Medicine, Japan
| | | | | | | | | | | |
Collapse
|
41
|
Kimura T, Shono M, Yokota S, Igata-Yi R, Takamatsu J, Miyakawa T. Apolipoprotein E epsilon3 allele is not a risk factor of schizophrenia: a study of 314 Japanese patients. Neuropsychobiology 2000; 42:66-8. [PMID: 10940761 DOI: 10.1159/000026675] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The association between apolipoprotein E (ApoE) alleles and schizophrenia has remained controversial. A recent report claiming that ApoE epsilon3 Taiwan Chinese carriers have an increased risk of schizophrenia prompted us to investigate the allele frequency in a large group of Japanese schizophrenic patients. Serum samples were obtained from 314 schizophrenic patients and 188 controls in Japan and examined using isoelectric focusing/immunoblotting. There were no significant differences in ApoE allele frequencies between schizophrenic patients and controls and in the odds ratios for schizophrenia among the epsilon2, epsilon3 and epsilon4 carriers. In contrast to the report from Taiwan, our findings and results of the majority of previous studies suggest no effects of ApoE alleles on the development of schizophrenia.
Collapse
Affiliation(s)
- T Kimura
- Department of Neuropsychiatry, Kumamoto University School of Medicine, Kumamoto, Japan.
| | | | | | | | | | | |
Collapse
|
42
|
Tatsunami S, Fukutake K, Taki M, Shirahata A, Mimaya J, Takamatsu J, Ueda Y, Yoshioka A, Takata N, Yamada K. Observed decline in the rate of death among Japanese hemophiliacs infected with HIV-1. Int J Hematol 2000; 72:256-7. [PMID: 11039680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
|
43
|
Abstract
The findings that free radicals play a causative role in the occurrence of tardive dyskinesia (TD) and that apolipoprotein E (ApoE) 4 has decreased anti-oxidant activity suggest a potential link between TD and ApoE alleles. We, therefore, examined ApoE allelic frequencies in schizophrenic subjects with TD and non-TD. Serum samples were obtained from 333 DSM IV-diagnosed schizophrenic patients and 191 controls in Japan. The presence of TD was evaluated by research diagnostic criteria for TD. ApoE phenotypes of the serum samples were determined by polyacrylamide gel isoelectricfocusing. A total of 62 TD subjects (31 males, 31 females) were identified among all patients examined. No significant differences in ApoE allelic frequency were found between TD and non-TD groups. ApoE epsilon4 allele frequency, however, was significantly lower in the female TD group than in the male TD group. These findings do not clearly demonstrate a certain association between TD and the epsilon4 allele, but may preliminarily reveal a difference in influence of this allele on the development of TD between males and females.
Collapse
Affiliation(s)
- T Kimura
- Department of Neuropsychiatry, Kumamoto University School of Medicine, Honjo 1-1-1, Kumamoto 860-8556, Japan.
| | | | | | | | | | | | | |
Collapse
|
44
|
Shirahata A, Fukutake K, Takamatsu J, Shima M, Yoshioka A. Pharmacokinetics, prophylactic effects, and safety of a new recombinant FVIII formulated with sucrose (BAY 14-2222) in Japanese patients with hemophilia A. Int J Hematol 2000; 72:101-7. [PMID: 10979218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
A clinical trial of BAY 14-2222, a recombinant factor VIII preparation (rFVIII) manufactured by new purification and formulation processes using sucrose as a stabilizer instead of human serum albumin, was performed in 5 previously treated Japanese patients with severe hemophilia A. In stage I, a single dose of BAY 14-2222 and Kogenate (a currently licensed rFVIII preparation) was administered alternately in the same patients to compare the pharmacokinetics of the 2 compounds using FVIII:C (FVIII clotting activity) as the measure of plasma drug levels. The normalized area under the curve (AUCnorm) and normalized maximal concentration (Cmax,norm) were slightly lower following the administration of BAY 14-2222 than those after the administration of Kogenate (ratio of BAY 14-2222/Kogenate:AUCnorm = 0.88, P = .050; and Cmax,norm = 0.87, P = .041). However, the biological half-life (t1/2) did not differ significantly between the 2 preparations (13.96 +/- 4.18 vs. 13.48 +/- 2.40 hours). The in vivo recovery of FVIII was 67.9 +/- 11.3% after the administration of BAY 14-2222 and 74.4 +/- 5.3% after the administration of Kogenate. In stage II, BAY 14-2222 was administered regularly to the 5 patients with hemophilia at single doses of 20 to 40 IU/kg 3 times weekly for 4 weeks, and its prophylactic effect on bleeding was evaluated. Results indicated that BAY 14-2222 has a good preventive effect on bleeding. Sixty-six infusions were performed in stages I and II of this trial, and no adverse reactions related to BAY 14-2222 were observed. In addition, there were no FVIII inhibitors or antibodies to foreign proteins detected. The trial confirmed that BAY 14-2222 is similar to Kogenate with respect to t1/2 and the in vivo recovery of FVIII:C and that periodic infusions for 4 weeks can be well tolerated. In addition, it was shown that BAY 14-2222 is effective in preventing bleeding. Thus it is expected that BAY 14-2222 will exhibit a hemostatic effect comparable to that of Kogenate in patients with hemophilia A.
Collapse
Affiliation(s)
- A Shirahata
- Department of Pediatrics, University of Occupational and Environmental Health, Kita-kyushu, Japan
| | | | | | | | | |
Collapse
|
45
|
Yasuda M, Takamatsu J, D'Souza I, Crowther RA, Kawamata T, Hasegawa M, Hasegawa H, Spillantini MG, Tanimukai S, Poorkaj P, Varani L, Varani G, Iwatsubo T, Goedert M, Schellenberg DG, Tanaka C. A novel mutation at position +12 in the intron following exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto). Ann Neurol 2000; 47:422-9. [PMID: 10762152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
Exonic and intronic mutations in the tau gene cause familial frontotemporal dementia and parkinsonism linked to chromosome 17. Here, we describe a new mutation, consisting of a C-to-T transition at position +12 of the intron following exon 10 of the tau gene in the Kumamoto pedigree, showing frontotemporal dementia. The mutation caused a marked reduction in melting temperature of the tau exon 10-splicing regulatory element RNA and a large increase in exon 10-containing transcripts. Brain tissue from affected individuals showed an abnormal preponderance of exon 10-containing transcripts that was reflected at the protein level by an overproduction of tau isoforms with four microtubule-binding repeats. Immunostaining revealed the presence of tau aggregates in degenerating neurons and glial cells. Isolated tau filaments had a twisted ribbon-like morphology and were made of hyperphosphorylated four-repeat tau isoforms. The additional mutation located dose to the splice-donor site of the intron following exon 10 of the tau gene supports the view that intronic mutations exercize their pathogenic effect by destabilizing RNA secondary structure.
Collapse
Affiliation(s)
- M Yasuda
- Hyogo Institute for Aging Brain and Cognitive Disorders, Himeji, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Kameoka K, Isotani H, Kitaoka H, Takamatsu J, Ohsawa N. Short stature is common feature of mitochondrial gene abnormalities with diabetes. Horm Metab Res 2000; 32:159-60. [PMID: 10824714 DOI: 10.1055/s-2007-978613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
47
|
Abstract
Activation of the amyloid beta-protein precursor, secretary pathway through alpha-secretase has been reported to increase the secretion of neuroprotective amyloid precursor protein and preclude the formation of amyloid beta-protein. Activation of protein kinase C has been shown to accelerate this secretory pathway. These results prompted us to focus on a potential links between protein kinase C and the amyloid beta-protein-related pathology of Alzheimer disease (AD). Although protein kinase C is reported to occur in senile plaques, its catalytic activity has not been investigated. As the phosphorylation of myristoylated alanine-rich C kinase substrate (MARCKS) has been used as a marker for activation of protein kinase C in vivo, we examined its phosphorylation in brain tissues obtained from seven AD patients and five non-demented subjects using an antibody that specifically recognized MARCKS phosphorylated by protein kinase C. Phosphorylation of MARCKS in cortical neurons in AD brains was weaker than that in control brains. Interestingly, however, phosphorylation of MARCKS was detected in microglia and dystrophic neurites within neuritic plaques, a mature form of amyloid beta-protein deposits. These results suggest that protein kinase C alteration is associated with AD pathology and that protein kinase C is activated in microglia and dystrophic neurites by amyloid beta-protein in AD brains.
Collapse
Affiliation(s)
- T Kimura
- Department of Neuropsychiatry, Kumamoto University School of Medicine, Japan
| | | | | | | | | | | |
Collapse
|
48
|
Amano K, Takamatsu J, Ogata A, Miyazaki C, Kaneyama H, Katsuragi S, Deshimaru M, Sumiyoshi S, Miyakawa T. Characteristics of epilepsy in severely mentally retarded individuals. Psychiatry Clin Neurosci 2000; 54:17-22. [PMID: 15558874 DOI: 10.1046/j.1440-1819.2000.00630.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
In order to clarify the characteristics of epilepsy in patients with severe mentally retarded (SMR) subjects, we analyzed 52 SMR subjects with epilepsy from the institute for SMR subjects at Kikuchi National Hospital, Kumamoto, Japan. A total of 61.5% patients had uncontrolled seizures which were resistant to treatment. The most common combinations of seizure types in those not responding to conventional anticonvulsants were generalized tonic-clonic seizures (GTCS) with tonic seizure and GTCS with atypical absence. Their clinical features were characterized by spastic paralysis associated with a slower background electroencephalogram and abnormal computed tomography scans of the head, suggesting the involvement of cortical damage. These findings suggest that a large proportion of epilepsy in SMR subjects does not respond to treatment and that the severity of organic brain damage may therefore affect the natural course of epilepsy in such patients.
Collapse
Affiliation(s)
- K Amano
- Department of Psychiatry, Kikuchi National Hospital, Kumamoto, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Toyoda H, Takahashi I, Fukuda Y, Hayakawa T, Takamatsu J. Comparison of characteristics between patients with GB virus C/hepatitis G virus (GBV-C/HGV) RNA and those with GBV-C/HGV E2-antibody in patients with hemophilia. J Med Virol 2000; 60:34-8. [PMID: 10568760 DOI: 10.1002/(sici)1096-9071(200001)60:1<34::aid-jmv6>3.0.co;2-#] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
We compared characteristics of patients with GB virus C/hepatitis G virus (GBV-C/HGV) RNA to those of patients with GBV-C/HGV E2-antibody. GBV-C/HGV RNA and GBV-C/HGV antibody were assayed in 83 persons with hemophilia using a reverse transcription-polymerase chain reaction and an enzyme-linked immunosorbent assay, respectively. GBV-C/HGV RNA was detected in 19 (22.9%) patients and GBV-C/HGV antibody was detected in 17 (20.5%). The background characteristics between the patient groups did not differ with respect to age, severity of hemophilia based on the frequency of use of blood product, and both the initial age at the first use and years since the first use of blood products. There were no differences in coinfection with hepatitis C virus (HCV) and/or human immunodeficiency virus, except that infection with HCV subtype 1a was more prevalent in patients with GBV-C/HGV RNA (P = 0.0229). Human lymphocyte antigen (HLA) typing was conducted in 18 patients with GBV-C/HGV RNA and 15 patients with GBV-C/HGV E2-antibody; 13 of the patients with GBV-C/HGV antibody had either HLA DQ7, DR15, or DR8, whereas only 4 of the patients with GBV-C/HGV RNA did (P < 0. 001). It is concluded that the presumed age at the time of GBV-C/HGV infection, the frequency of exposure to GBV-C/HGV, and the time since the GBV-C/HGV infection were not associated with recovery from infection with GBV-C/HGV. Coinfection with HCV subtype 1a may be related to persistent GBV-C/HGV viremia, whereas HLA DQ7, DR15, or DR8 may be related to the clearance of GBV-C/HGV after infection.
Collapse
Affiliation(s)
- H Toyoda
- Second Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan
| | | | | | | | | |
Collapse
|
50
|
Hasegawa Y, Takamatsu J, Iwase T, Iwasada S, Kitamura S, Iwata H. Effects of recombinant human erythropoietin on thrombosis and fibrinolysis in autologous transfusion for hip surgery. Arch Orthop Trauma Surg 1999; 119:384-7. [PMID: 10613225 DOI: 10.1007/s004020050434] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Recombinant human erythropoietin (rHuEPO) is effective in allowing autologous blood donation in patients unable to donate because of anemia. As adverse effects of rHuEPO might include activation of coagulation and possibly fibrinolysis, we investigated these possibilities in the context of autologous blood donation preceding hip surgery. Thirty-seven patients who donated 800 ml of autologous blood for elective hip surgery were randomly assigned to either a group of 20 receiving preoperative treatment with rHuEPO (erythropoietin beta), 6000 U i.v. twice weekly for 3 weeks, or an untreated control group of 17. A significant increase in platelet count was associated with autologous blood donation and intraoperative blood loss with or without rHuEPO. Coagulation and fibrinolysis were increased significantly by intraoperative blood loss in both groups, but not by rHuEPO. Coagulation and fibrinolysis were not activated by rHuEPO for elective hip surgery.
Collapse
Affiliation(s)
- Y Hasegawa
- Department of Orthopaedic Surgery, Nagoya University School of Medicine, Japan
| | | | | | | | | | | |
Collapse
|